Familiární hypercholesterolémie: co potřebuje vědět kardiolog

Title in English Familial hypercholesterolemia: what a cardiologist needs to know

SOŠKA Vladimír KYSELÁK Ondřej

Year of publication 2016
Type Article in Periodical
Magazine / Source Postgraduální medicína
MU Faculty or unit

Faculty of Medicine

Field Cardiovascular diseases incl. cardiosurgery
Keywords familiar hypercholesterolemia; LDL cholesterol; cardiovascular disease; statins; PCSK9 inhibitors
Description Familial hypercholesterolemia is from the clinical point of view the most serious form of congenital lipid metabolism defect. Patients with familial hypercholesterolemia have a high risk of very early cardiovascular diseases, especially myocardium infarctions. Because familiar hypercholesterolemia is practically asymptomatic until the cardiovascular complications manifest, it is necessary to actively screen for patients suffering from it and to give them a timely, aggressive and lifelong treatment. There is a network of specialised centres in the Czech Republic, which provide diagnostics, monitoring and treatment to such patients (project MedPed). The foundation of the treatment are high doses of statins, usually in a combination with ezetimibe, but even that is not sufficient in most patients to reach target levels of LDL cholesterol. New drugs from the PCSK9 inhibitor group should bring a serious improvement to the prognosis of patients with familial hypercholesterolemia, enabling them to reach target levels of LDL cholesterol and thus to prevent cardiovascular complications.

You are running an old browser version. We recommend updating your browser to its latest version.

More info